Beyond sorafenib: novel targeted therapies for advanced hepatocellular carcinoma. - Wikidata - awgldk - TriplyDB

Beyond sorafenib: novel targeted therapies for advanced hepatocellular carcinoma.

Beyond sorafenib: novel targeted therapies for advanced hepatocellular carcinoma.

http://www.wikidata.org/entity/Q37724256

about

Recombinant human acid sphingomyelinase as an adjuvant to sorafenib treatment of experimental liver cancer Integrating recent data in managing adverse events in the treatment of hepatocellular carcinoma.New progress of non-surgical treatments for hepatocellular carcinoma.Therapeutic options for intermediate-advanced hepatocellular carcinoma.Increasing incidence of brain metastasis in patients with advanced hepatocellular carcinoma in the era of antiangiogenic targeted therapy.HBx sensitizes hepatocellular carcinoma cells to lapatinib by up-regulating ErbB3.Targeting therapy of hepatocellular carcinoma with doxorubicin prodrug PDOX increases anti-metastatic effect and reduces toxicity: a preclinical study Role of the multidisciplinary team in the diagnosis and treatment of hepatocellular carcinoma.The important roles of RET, VEGFR2 and the RAF/MEK/ERK pathway in cancer treatment with sorafenib.Recombinant hHscFv-RC-RNase protein derived from transgenic tobacco acts as a bifunctional molecular complex against hepatocellular carcinoma.

P2860

Q28533335-73A9F852-40CD-4187-8D90-6B047B78C92C Q34197835-7069B11A-A883-49E0-A1FF-2EB8439FF968 Q34647076-4FB87C47-634C-442D-81FC-937F6FAE2599 Q34771990-890C5FAA-8119-459D-B844-DDF61626CC97 Q35584330-9C34289B-1031-4E69-B99C-A292194DAC10 Q36729450-CB07B828-1A0B-474C-9637-F508B641C067 Q37153412-A48E8440-B1BA-4688-B419-F3F6E67A9972 Q37989160-870A2E5E-62C2-474A-9AD2-F0CAD45B32BA Q39017645-760B35FD-BD4F-4481-AEBF-58640124BE87 Q39166282-F771A78F-4432-44D7-8276-1DF5A8DC747F

P2860

Beyond sorafenib: novel targeted therapies for advanced hepatocellular carcinoma.

http://www.wikidata.org/entity/Q37724256

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on May 2010

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Beyond sorafenib: novel targeted therapies for advanced hepatocellular carcinoma.

@en

Beyond sorafenib: novel targeted therapies for advanced hepatocellular carcinoma.

@nl

type

label

Beyond sorafenib: novel targeted therapies for advanced hepatocellular carcinoma.

@en

Beyond sorafenib: novel targeted therapies for advanced hepatocellular carcinoma.

@nl

prefLabel

Beyond sorafenib: novel targeted therapies for advanced hepatocellular carcinoma.

@en

Beyond sorafenib: novel targeted therapies for advanced hepatocellular carcinoma.

@nl

P1433

Q37724256-68DBFE40-BE5B-4F0D-ACBA-54DDA666FB2A

P1476

Q37724256-9DD307D2-9069-4C04-AAEE-7E77A2D246DC

P2093

Q37724256-BFAEA006-BA83-428B-BFF0-966B4257662A

P2860

Q37724256-0139C932-B52D-4FC6-AB1D-8689413496AC

Q37724256-02D803D0-B97D-401E-98E8-DE70132CD59C

Q37724256-06709552-016F-414E-9CE6-787B2AA6C70E

Q37724256-1A9BE76F-39CA-4230-A8A1-03A952432184

Q37724256-302989F6-4472-4723-9A2A-C411FB28B74D

Q37724256-348E7EE1-83F0-41B4-9022-42F95F02B474

Q37724256-349F2C6D-4E4B-440A-917C-8B180E128684

Q37724256-3751C378-E340-42EF-8863-A236A59904EF

Q37724256-3D7DD1E1-3656-42AD-A0BF-336CACF86527

Q37724256-4EB055B3-61AA-4A30-8E35-56708376D726

P304

Q37724256-A34E7057-6CFE-4D3C-B4C2-7ABBEA47B65A

P31

Q37724256-0953C230-DB7F-4545-87C6-A808C5AC3E29

P356

Q37724256-B4A055CF-BC53-46EF-919F-5E67E32A0C1B

P407

Q37724256-802A4915-920A-48AC-AFAF-B2B7CBEF9FD2

P433

Q37724256-110DB866-B7F9-4A1B-B9C4-C5894FA0726B

P478

Q37724256-5069EEC6-76DB-4630-B42A-CB6948027EB4

P577

Q37724256-8B351984-F7A9-4A11-8457-1F22C54AC968

P698

Q37724256-DD29F616-918D-427E-AF02-2857511E3DFD

P356

13543781003767426

P1433

Expert Opinion on Investigational Drugs

P1476

Beyond sorafenib: novel targeted therapies for advanced hepatocellular carcinoma.

@en

P2093

Andrew X Zhu

http://www.w3.org/2001/XMLSchema#string

P2860

Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: its role in tumor progression and apoptosis

Microvessel density and clinicopathological characteristics in hepatitis C virus and hepatitis B virus related hepatocellular carcinoma

Global cancer statistics, 2002

Sorafenib in advanced hepatocellular carcinoma

AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study.

Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma.

Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study.

Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study.

P304

663-672

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/13543781003767426

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P577

2010-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20367287

http://www.w3.org/2001/XMLSchema#string